News items related to: Patent Challenges

  • Storify: Pathways to Access #GSIPA2M

    [View the story “Pathways to Access! #GSIPA2M (15-17 Jan 2018)” on Storify] SaveSave

  • GSIPA2M: The Summit Highlights

    Catch up on the activity from our inaugural Global Summit on Intellectual Property and Access to Medicines (15-17 January 2018)....

  • IP and access to medicines: welcome speech

    Our inaugural Global Summit on Intellectual Property and Access to Medicines has started today. Read Solange Baptiste’s welcoming speech below,...

  • Pathways to Access: Our global summit on intellectual property and access to medicines

    23 years after the Trade Related Aspects of Intellectual Property Rights (TRIPS) Agreement was signed in Morocco, our inaugural conference...

  • Argentina: Patent rejected on hepatitis C drug, sofosbuvir

    A decision by the patent office in Argentina (INPI) to reject Gilead’s patent on key hepatitis C drug, sofosbuvir, is...

  • ‘Questionable’ patent on key HIV drug is challenged in Brazil

    Legal challenge essential to prevent further barriers to optimal HIV treatment in Brazil. ABIA, our campaign partner in Brazil, is...

  • HIV activists trained on intellectual property and access to medicines

      Demystifying intellectual property (IP) and providing advocacy tools. The International Treatment Preparedness Coalition – MENA (ITPC-MENA) with the support...

  • The Network vs. Abbvie – the first victory in reducing cost of HIV drug

    The first victory has been won – and our partner in Ukraine intends to see the case through. On 4...

  • Patients demand AbbVie’s price bubble is burst – key HIV drug out of reach

    AbbVie’s monopoly has hiked prices – it’s time to burst the bubble and get prices back down to earth. Activists...

  • Tackling the hepatitis C epidemic in Malaysia

    With new, revolutionary, drugs available, why isn’t everyone getting the cure? An estimated 454,000 people are living with hepatitis C...